AAPL   299.31 (-4.39%)
FB   199.00 (-5.32%)
MSFT   171.68 (-3.87%)
GOOGL   1,415.36 (-4.59%)
AMZN   1,995.68 (-4.78%)
CGC   20.38 (-6.86%)
NVDA   275.35 (-6.37%)
BABA   204.19 (-3.95%)
MU   54.60 (-4.19%)
GE   11.88 (-3.10%)
TSLA   833.35 (-7.51%)
AMD   49.18 (-7.71%)
T   38.15 (-1.04%)
ACB   1.56 (-7.16%)
F   7.61 (-3.55%)
NFLX   366.23 (-3.64%)
BAC   32.67 (-4.95%)
DIS   131.48 (-5.39%)
AAPL   299.31 (-4.39%)
FB   199.00 (-5.32%)
MSFT   171.68 (-3.87%)
GOOGL   1,415.36 (-4.59%)
AMZN   1,995.68 (-4.78%)
CGC   20.38 (-6.86%)
NVDA   275.35 (-6.37%)
BABA   204.19 (-3.95%)
MU   54.60 (-4.19%)
GE   11.88 (-3.10%)
TSLA   833.35 (-7.51%)
AMD   49.18 (-7.71%)
T   38.15 (-1.04%)
ACB   1.56 (-7.16%)
F   7.61 (-3.55%)
NFLX   366.23 (-3.64%)
BAC   32.67 (-4.95%)
DIS   131.48 (-5.39%)
AAPL   299.31 (-4.39%)
FB   199.00 (-5.32%)
MSFT   171.68 (-3.87%)
GOOGL   1,415.36 (-4.59%)
AMZN   1,995.68 (-4.78%)
CGC   20.38 (-6.86%)
NVDA   275.35 (-6.37%)
BABA   204.19 (-3.95%)
MU   54.60 (-4.19%)
GE   11.88 (-3.10%)
TSLA   833.35 (-7.51%)
AMD   49.18 (-7.71%)
T   38.15 (-1.04%)
ACB   1.56 (-7.16%)
F   7.61 (-3.55%)
NFLX   366.23 (-3.64%)
BAC   32.67 (-4.95%)
DIS   131.48 (-5.39%)
AAPL   299.31 (-4.39%)
FB   199.00 (-5.32%)
MSFT   171.68 (-3.87%)
GOOGL   1,415.36 (-4.59%)
AMZN   1,995.68 (-4.78%)
CGC   20.38 (-6.86%)
NVDA   275.35 (-6.37%)
BABA   204.19 (-3.95%)
MU   54.60 (-4.19%)
GE   11.88 (-3.10%)
TSLA   833.35 (-7.51%)
AMD   49.18 (-7.71%)
T   38.15 (-1.04%)
ACB   1.56 (-7.16%)
F   7.61 (-3.55%)
NFLX   366.23 (-3.64%)
BAC   32.67 (-4.95%)
DIS   131.48 (-5.39%)
Log in

NASDAQ:PRQR - ProQR Therapeutics Stock Price, Forecast & News

$8.21
-0.83 (-9.18 %)
(As of 02/24/2020 12:32 PM ET)
Today's Range
$8.21
Now: $8.21
$8.76
50-Day Range
$7.03
MA: $8.30
$9.24
52-Week Range
$5.49
Now: $8.21
$16.07
Volume7,575 shs
Average Volume202,339 shs
Market Capitalization$405.33 million
P/E RatioN/A
Dividend YieldN/A
Beta0.41
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRQR
CUSIPN/A
Phone31-88-166-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.83 per share

Profitability

Net Income$-43,570,000.00

Miscellaneous

Employees118
Market Cap$405.33 million
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive PRQR News and Ratings via Email

Sign-up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter.


ProQR Therapeutics (NASDAQ:PRQR) Frequently Asked Questions

What is ProQR Therapeutics' stock symbol?

ProQR Therapeutics trades on the NASDAQ under the ticker symbol "PRQR."

How were ProQR Therapeutics' earnings last quarter?

ProQR Therapeutics NV (NASDAQ:PRQR) released its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.31) by $0.10. View ProQR Therapeutics' Earnings History.

When is ProQR Therapeutics' next earnings date?

ProQR Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for ProQR Therapeutics.

What price target have analysts set for PRQR?

4 brokerages have issued twelve-month target prices for ProQR Therapeutics' shares. Their forecasts range from $20.00 to $40.00. On average, they anticipate ProQR Therapeutics' share price to reach $28.00 in the next year. This suggests a possible upside of 241.0% from the stock's current price. View Analyst Price Targets for ProQR Therapeutics.

What is the consensus analysts' recommendation for ProQR Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProQR Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ProQR Therapeutics.

What are Wall Street analysts saying about ProQR Therapeutics stock?

Here are some recent quotes from research analysts about ProQR Therapeutics stock:
  • 1. According to Zacks Investment Research, "ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company's lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. " (1/11/2020)
  • 2. HC Wainwright analysts commented, "Our price target of $20/share is based on an equally-weighted composite of: (a) $20.7/share, as a 25x multiple of taxed and diluted $10.07 discounted back to FY19 at 32% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $18.8/ share (discounted cash flow analysis using a 22% discount rate and 2.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (2/28/2019)

Has ProQR Therapeutics been receiving favorable news coverage?

Media coverage about PRQR stock has trended very negative this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ProQR Therapeutics earned a daily sentiment score of -3.2 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for ProQR Therapeutics.

Who are some of ProQR Therapeutics' key competitors?

What other stocks do shareholders of ProQR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProQR Therapeutics investors own include Bioamber (BIOA), GALAPAGOS NV/S (GLPG), Corbus Pharmaceuticals (CRBP), TG Therapeutics (TGTX), Sorrento Therapeutics (SRNE), Uniqure (QURE), SCYNEXIS (SCYX), Viking Therapeutics (VKTX), Verastem (VSTM) and Progenics Pharmaceuticals (PGNX).

Who are ProQR Therapeutics' key executives?

ProQR Therapeutics' management team includes the folowing people:
  • Mr. Daniel Anton de Boer, CEO & Member of Management Board (Age 36)
  • Ms. Smital Shah, Chief Bus. & Financial Officer (Age 43)
  • Ms. Lisa A. Hayes, VP of Investor Relations & Corp. Communications
  • Mr. Bart Klein, Sr. VP of Intellectual Property
  • Mr. Gerard Platenburg, Chief Innovation Officer & Chairman of Advisory Board (Age 55)

Who are ProQR Therapeutics' major shareholders?

ProQR Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Goldman Sachs Group Inc. (6.79%), Jennison Associates LLC (5.33%), FMR LLC (2.39%), UBS Group AG (1.03%), Cowen AND Company LLC (0.21%) and Renaissance Technologies LLC (0.17%).

Which major investors are selling ProQR Therapeutics stock?

PRQR stock was sold by a variety of institutional investors in the last quarter, including State Street Corp and Renaissance Technologies LLC.

Which major investors are buying ProQR Therapeutics stock?

PRQR stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Cowen AND Company LLC, UBS Group AG, California Public Employees Retirement System, Goldman Sachs Group Inc., Geode Capital Management LLC, Oxford Asset Management LLP and Ellington Management Group LLC.

How do I buy shares of ProQR Therapeutics?

Shares of PRQR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ProQR Therapeutics' stock price today?

One share of PRQR stock can currently be purchased for approximately $8.21.

How big of a company is ProQR Therapeutics?

ProQR Therapeutics has a market capitalization of $405.33 million. The biopharmaceutical company earns $-43,570,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. ProQR Therapeutics employs 118 workers across the globe.View Additional Information About ProQR Therapeutics.

What is ProQR Therapeutics' official website?

The official website for ProQR Therapeutics is http://www.proqr.com/.

How can I contact ProQR Therapeutics?

ProQR Therapeutics' mailing address is Zernikedreef 9, Leiden P7, 2333 CK. The biopharmaceutical company can be reached via phone at 31-88-166-7000 or via email at [email protected]


MarketBeat Community Rating for ProQR Therapeutics (NASDAQ PRQR)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  257 (Vote Outperform)
Underperform Votes:  265 (Vote Underperform)
Total Votes:  522
MarketBeat's community ratings are surveys of what our community members think about ProQR Therapeutics and other stocks. Vote "Outperform" if you believe PRQR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRQR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Featured Article: Overbought

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel